Galectin <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports Q3 2025 financial results and updates on belapectin trial data
Galectin Therapeutics Inc. reported a net loss applicable to common stockholders of $8.2 million, or ($0.13) per share, for the quarter ended September 30, 2025, compared to a net loss of $11.2 million, or ($0.18) per share, for the same period in 2024. Research and development expenses were $2.6 million, down from $7.6 million in the prior year, primarily due to the conclusion of expenditures related to the NAVIGATE clinical trial. General and administrative expenses were $1.6 million, compared to $1.5 million in the previous year. As of September 30, 2025, the company held $11.5 million in cash and cash equivalents and entered into a $10 million line of credit in July 2025. The company submitted the NAVIGATE data package to the FDA and expects guidance by year-end, with sufficient cash to fund current plans through June 30, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-042118), on November 14, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。